HomeInsightsPE

Medicamen Biotech Ltd PE Ratio

Medicamen Biotech Ltd PE Ratio

stocks purchased

₹ 0.4 Cr

Volume Transacted

(Dec 11, 2024)

stocks purchased

7.0 K

Stocks Traded

(Dec 11, 2024)

Last Updated on: Dec 11, 2024

Image

Medicamen Biotech Ltd

NSE: MEDICAMEQ

PE

100.7

Last updated on: Dec 11, 2024

Key Highlights

  • The P/E Ratio of Medicamen Biotech Ltd is 100.7 as of 11 Dec 9.00 AM .
  • The P/E Ratio of Medicamen Biotech Ltd changed from 47.2 on March 2019 to 44.5 on March 2024 . This represents a CAGR of -0.98% over 6 years.
  • The Latest Trading Price of Medicamen Biotech Ltd is ₹ 580.75 as of 11 Dec 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.5. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Medicamen Biotech Ltd

No data available

Company Fundamentals for Medicamen Biotech Ltd

No data available

Image

Medicamen Biotech Ltd

NSE: MEDICAMEQ

Share Price

₹ 580.75

-23.75 (-3.93%)

stock direction

Last updated on: Dec 11, 2024

Market Price of Medicamen Biotech Ltd

1M

1Y

3Y

5Y

Monitoring Medicamen Biotech Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
11 Dec 2024580.75
10 Dec 2024604.5
09 Dec 2024598.6
06 Dec 2024606.7
05 Dec 2024583.4
04 Dec 2024528.75
03 Dec 2024488.45
02 Dec 2024449.4
29 Nov 2024443.6
28 Nov 2024439.05

SWOT Analysis Of Medicamen Biotech Ltd

Strength

4

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Medicamen Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Medicamen Biotech Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Medicamen Biotech Ltd100738
Sun Pharmaceuticals Industries Ltd384,35,407
Divis Laboratories Ltd851,57,489
Cipla Ltd251,17,443
Torrent Pharmaceuticals Ltd651,14,197
Mankind Pharma Ltd491,05,098

Key Valuation Metric of Medicamen Biotech Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Medicamen Biotech Ltd

No data available

* All values are in crore

Historical Revenue of Medicamen Biotech Ltd

No data available

* All values are in crore

Historical EBITDA of Medicamen Biotech Ltd

No data available

* All values are in crore

Historical Net Profit of Medicamen Biotech Ltd

No data available

* All values are in crore

Historical Dividend Payout of Medicamen Biotech Ltd

No data available

* All values are in %

About Medicamen Biotech Ltd

  • Medicamen Biotech Ltd is a widely held, Globally Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.
  • The company is engaged in manufacture and distribution of medicines.
  • They manufacturer and supply the range of products such as tablets, capsules, liquid syrup and dry syrup (beta lactum and non beta lactum) and ointment. The company has two manufacturing facilities namely, Bhiwadi (Rajasthan) and Haridwar (Uttarakhand).
  • The Bhiwadi unit has ultra modern production facilities incorporating latest state of the art technology with a combination of technically qualified personnel and hardworking workforce.
  • In Haridwar unit, the company manufactures Non-Betalactum preparations including tablets, capsules, oral liquids and ointments & creams.

Medicamen Biotech Ltd News Hub

News

Medicamen Biotech consolidated net profit declines 67.70% in the June 2024 quarter

Net profit of Medicamen Biotech declined 67.70% to Rs 1.35 crore in the quarter ended June...

Read more

2024-08-13 00:00:00

News

Medicamen Biotech to conduct board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 13 Augus...

Read more

2024-08-12 00:00:00

News

Medicamen Biotech to conduct AGM

Medicamen Biotech announced that the Annual General Meeting (AGM) of the company will be h...

Read more

2024-09-13 00:00:00

News

Medicamen Biotech declare Quarterly Result

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 14 Novem...

Read more

2024-11-08 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Medicamen Biotech Ltd

What is the current PE Ratio of Medicamen Biotech Ltd?

The Current PE Ratio of Medicamen Biotech Ltd is 100.65 as on 11 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 11 Dec 2024.

What was the PE Ratio of Medicamen Biotech Ltd last year?

The PE Ratio of Medicamen Biotech Ltd was 55.89 last year, now the PE ratio is 100.65, showing a year-on-year growth of 80.1%.

What does the PE Ratio of Medicamen Biotech Ltd indicate about its stock?

The PE Ratio of Medicamen Biotech Ltd is 100.65. This ratio indicates that investors are willing to pay 100.65 times the earnings per share for each share of Medicamen Biotech Ltd.

What is the PE Ratio Growth of Medicamen Biotech Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Medicamen Biotech Ltd grew by 80.1% whereas, the EPS ratio grew by 12.7.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions